Controlling cell-free expression with temperature-sensitive polymer-DNA conjugates
Controlling cell-free expression with temperature-sensitive polymer-DNA conjugates
批准号:
EP/V030434/2
负责人:
Michael Booth
金额:
$24.04万
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2022
资助国家:
英国
项目状态:
已结题
起止时间:
2022 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
In living cells, genomic DNA is transcribed to RNA, then translated to protein, in a process called expression. The RNA and protein produced from expression is then involved in all manner of cellular processes, from membrane signalling to control of expression itself. It is possible to carry out expression without the presence of a cell; this is known as cell-free expression (CFE). CFE systems have been used to construct gene circuits, DNA computers, lab-on-a-chip devices, and synthetic cells, which can be used in a wide range of applications, from studying how cells work to developing and screening therapeutics. Control of CFE using external stimuli is vital for future applications because it will allow precise activation and repression of expression upon demand. Current methods of control rely on small-molecule activators and light, which suffer from a lack of spatiotemporal control and low tissue penetration, respectively. An external stimulus that addresses both these limitations is temperature. Temperature is an optimal stimulus for both in-vitro and in-vivo use as it has high tissue penetration and can be spatiotemporally controlled using ultrasound. It has previously been demonstrated that cellular systems and therapeutics can be controlled by heating to just above body temperature, otherwise known as mild hyperthermia, without toxicity issues. In the research proposed here, we aim to control CFE using mild hyperthermia temperatures. A common way of controlling therapeutics with temperature is to use smart materials made from temperature-sensitive polymers. These function by changing from soluble coils at one temperature to insoluble globules at another temperature. Temperature-sensitive polymer-based drug delivery technologies have been successfully used in clinical trials, demonstrating their safety and efficacy. The most widely-used temperature-sensitive polymers have a lower critical solution temperature (LCST), meaning they become insoluble upon an increase in temperature. Temperature-sensitive polymers with an upper critical solution temperature (UCST) also exist; these become soluble upon an increase in temperature. Both LCST and UCST polymers have previously been synthesised that have critical temperatures in the mild hyperthermia range.Here, control of CFE will be achieved by attaching UCST polymers to DNA. Many studies have connected LCST polymers to DNA to control its structure and function, although only a few have attempted to control CFE. Our goal is to create a system where, at body temperature, UCST polymers connected to DNA will form globules that inhibit CFE. Upon heating to mild hyperthermia temperatures, above the UCST, the UCST polymers will change from insoluble globules to soluble coils, activating CFE. This process will be reversible and can be controlled by again reducing the temperature below the UCST. The use of UCST polymers, rather than LCST polymers, is necessary for our studies as we require activation of CFE upon an increase in temperature. We will synthesise novel and previously published UCST polymers that function in the mild hyperthermia range. Their properties will be studied before and after they have been attached to DNA. Optimal UCST polymers attached to different DNAs will then be used for reversible control of CFE using mild hyperthermia temperatures. There has been no previous research on UCST polymers attached to DNA and, since multiple applications have arisen from LCST polymers attached to DNA, studying UCST-polymers attached to DNA might lead to the identification of novel applications. In the future, our method of controlling DNA using temperature-sensitive polymers and mild hyperthermia could be used to develop controllable cell-free technologies or to control alternative DNA and RNA therapeutics.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Precise, orthogonal remote-control of cell-free systems using photocaged nucleic acids
使用光笼核酸对无细胞系统进行精确、正交的远程控制
DOI:
10.26434/chemrxiv-2023-ssv30
发表时间:
2023
期刊:
影响因子:
--
作者:
[Mazzotti G]
通讯作者:
Mazzotti G
Handcuffed antisense oligonucleotides for light-controlled cell-free expression.
用于光控无细胞表达的手铐反义寡核苷酸。
DOI:
10.1039/d3cc01374j
发表时间:
2023
期刊:
Chemical communications (Cambridge, England)
影响因子:
--
作者:
[Hartmann D]
通讯作者:
Hartmann D
DOI:
10.1038/s42004-023-00860-2
发表时间:
2023-04-01
期刊:
COMMUNICATIONS CHEMISTRY
影响因子:
5.9
作者:
[Hartmann, Denis, Booth, Michael J.]
通讯作者:
Booth, Michael J.
DOI:
10.1038/s41589-023-01374-7
发表时间:
2023-09
期刊:
NATURE CHEMICAL BIOLOGY
影响因子:
14.8
作者:
[Smith, Jefferson M., Hartmann, Denis, Booth, Michael J.]
通讯作者:
Booth, Michael J.
SIGSYNCELL: Engineering biological signaling pathways using synthetic cells
-
批准号:EP/Y032675/1
-
项目类别:Research Grant
-
资助金额:$33.22万
-
财政年份:2024
-
负责人:Michael Booth
-
依托单位:
21ENGBIO A Universal and Controllable Interface between Synthetic Cells and Living Cells
-
批准号:BB/W011468/1
-
项目类别:Research Grant
-
资助金额:$12.84万
-
财政年份:2023
-
负责人:Michael Booth
-
依托单位:
Controlling cell-free expression with temperature-sensitive polymer-DNA conjugates
-
批准号:EP/V030434/1
-
项目类别:Research Grant
-
资助金额:$36.21万
-
财政年份:2021
-
负责人:Michael Booth
-
依托单位:
国内基金
海外基金
登录
查看更多内容
全细胞疫苗Cell@MnO2的乳腺癌术后免疫响应监测与放射免疫治疗研究
-
批准号:QN25H220002
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:顾媛
-
依托单位:
染色体外环状DNA以cell-in-cell途径促进基因横向传递和扩增的研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:王锐智
-
依托单位:
GMFG/F-actin/cell adhesion 轴驱动 EHT 在造
血干细胞生成中的作用及机制研究
-
批准号:TGY24H080011
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:李鸿鹄
-
依托单位:
糖尿病ED中成纤维细胞衰老调控内皮细胞线粒体稳态失衡的机制研究
-
批准号:82371634
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:赵福军
-
依托单位:
基于In-cell NMR策略对“舟楫之剂”桔梗中引经药效物质的快速发现研究
-
批准号:82305053
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:王丽明
-
依托单位:
配子生成素GGN不同位点突变损伤分子伴侣BIP及HSP90B1功能导致精子形成障碍的发病机理
-
批准号:82371616
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:姚晨成
-
依托单位:
骨髓ISG+NAMPT+中性粒细胞介导抗磷脂综合征B细胞异常活化的机制研究
-
批准号:82371799
-
项目类别:面上项目
-
资助金额:47.00万元
-
批准年份:2023
-
负责人:杨程德
-
依托单位:
利用CRISPR内源性激活Atoh1转录促进前庭毛细胞再生和功能重建
-
批准号:82371145
-
项目类别:面上项目
-
资助金额:46.00万元
-
批准年份:2023
-
负责人:陶永
-
依托单位:
IL-4协同精氨酸优化种植初期巨噬细胞胞葬作用和成骨微环境的作用及机制研究
-
批准号:82370923
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:张文杰
-
依托单位:
胆固醇合成蛋白CYP51介导线粒体通透性转换诱发Th17/Treg细胞稳态失衡在舍格伦综合征中的作用机制研究
-
批准号:82370976
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:郑凌艳
-
依托单位: